1
|
Bellanca CM, Augello E, Di Benedetto G, Burgaletto C, Cantone AF, Cantarella G, Bernardini R, Polosa R. A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy. Front Pharmacol 2024; 15:1406860. [PMID: 38957391 PMCID: PMC11217182 DOI: 10.3389/fphar.2024.1406860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Accepted: 05/20/2024] [Indexed: 07/04/2024] Open
Abstract
Currently 1.3 billion individuals globally engage in smoking, leading to significant morbidity and mortality, particularly among diabetic patients. There is urgent need for a better understanding of how smoking influences antidiabetic treatment efficacy. The review underscores the role of cigarette smoke, particularly polycyclic aromatic hydrocarbons (PAHs), in modulating the metabolic pathways of antidiabetic drugs, primarily through the induction of cytochrome P450 (CYP450) enzymes and uridine diphosphate (UDP)-glucuronosyltransferases (UGTs), thus impacting drug pharmacokinetics and therapeutic outcomes. Furthermore, the review addresses the relatively uncharted territory of how smoking cessation influences diabetes treatment, noting that cessation can lead to significant changes in drug metabolism, necessitating dosage adjustments. Special attention is given to the interaction between smoking cessation aids and antidiabetic medications, a critical area for patient safety and effective diabetes management. This scoping review aims to provide healthcare professionals with the knowledge to better support diabetic patients who smoke or are attempting to quit, ensuring tailored and effective treatment strategies. It also identifies gaps in current research, advocating for more studies to fill these voids, thereby enhancing patient care and treatment outcomes for this at-risk population.
Collapse
Affiliation(s)
- Carlo Maria Bellanca
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- Clinical Toxicology Unit, University Hospital of Catania, Catania, Italy
| | - Egle Augello
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- Clinical Toxicology Unit, University Hospital of Catania, Catania, Italy
| | - Giulia Di Benedetto
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- Clinical Toxicology Unit, University Hospital of Catania, Catania, Italy
| | - Chiara Burgaletto
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
| | - Anna Flavia Cantone
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
| | - Giuseppina Cantarella
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
| | - Renato Bernardini
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- Clinical Toxicology Unit, University Hospital of Catania, Catania, Italy
| | - Riccardo Polosa
- Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
- Centre of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), University Hospital of Catania, Catania, Italy
| |
Collapse
|
2
|
Patel T, Patel V. Thiazolidinediones: Recent Development in Analytical Methodologies. J Chromatogr Sci 2023:bmad058. [PMID: 37539627 DOI: 10.1093/chromsci/bmad058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 05/31/2023] [Indexed: 08/05/2023]
Abstract
The instrumental analytical methods that have been developed and utilized for the determination of thiazolidinedione in bulk medications, formulations and biological fluids have been reviewed after an in-depth analysis of the literature published in a variety of analytical and pharmaceutical chemistry-related journals. The approaches covered by this research, which covers the years 2001-2022, include complex methods for analysis, chromatographic techniques and spectrometric analytical procedures. The mobile phase, flow rate, sample matrix, wavelength and other factors identified in the literature were just a few of the parameters used to evaluate thiazolidinediones. The present review focuses on the published analytical techniques for thiazolidinedione analysis that have been previously identified in the literature. The specified outcomes followed extensive learning, and the most recent advances in analytical methods for the identification of pioglitazone, pioglitazone HCl, rosiglitazone, rosiglitazone maleate and lobeglitazone were reviewed. Additionally, this article briefly discusses features of analytical discovery on thiazolidinediones, which will enable readers to access all discoveries in one place with precise outcomes.
Collapse
Affiliation(s)
- Tarang Patel
- Department of Pharmaceutical Quality Assurance, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat Campus, Changa 388 421, Gujarat, India
| | - Vatsal Patel
- Department of Pharmaceutical Analysis, Sardar Patel Education Campus, SPEC Campus, Vidyanagar-Vadtal Road Bakrol 388 315, Gujarat, India
| |
Collapse
|
3
|
Stamou P, Parla A, Kabir A, Furton KG, Gennimata D, Samanidou V, Panderi I. Hydrophilic interaction liquid chromatography-electrospray ionization mass spectrometry combined with fabric phase sorptive extraction for therapeutic drug monitoring of pioglitazone, repaglinide, and nateglinide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1217:123628. [PMID: 36801529 DOI: 10.1016/j.jchromb.2023.123628] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 02/02/2023] [Accepted: 02/06/2023] [Indexed: 02/11/2023]
Abstract
Polypharmacy in type 2 diabetes is an issue of major concern as the prescription of multiple medi-cations for the management of diabetes-associated comorbidities can lead to drug-to-drug interactions, which can pose serious risks to patients' health. Within this context, the development of bioanalytical methods for monitoring the therapeutic levels of antidiabetic drugs is notably useful to ensure patients' safety. In the present work, a liquid chromatography-mass spectrometry method for the quantitation of pioglitazone, repaglinide, and nateglinide in human plasma is described. Sample preparation was performed by fabric phase sorptive extraction (FPSE), and hydrophilic interaction liquid chromatography (HILIC) was implemented for the chromatographic separation of the analytes, using a ZIC®-cHILIC analytical column (150 × 2.1 mm, 3 µm) under isocratic elution. The mobile phase consisted of 10 mM ammonium formate aqueous solution (pH = 6.5)/ acetonitrile, 10/90 v/v, and was pumped at a flow rate of 0.2 mL min-1. Design of Experiments was used during the development of the sample preparation method to gain deeper insight into the effect of various experimental parameters on extraction efficiency, their potential interactions and to optimize the recovery rates of the analytes. The linearity of the assay was assessed over the ranges of 25 to 2000, 6.25 to 500, and 125 to 10000 ng mL-1 for pioglitazone, repaglinide, and nateglinide, respectively. The presented method was fully validated and can be used for the therapeutic monitoring of the targeted analytes in human plasma samples.
Collapse
Affiliation(s)
- Panagiotis Stamou
- Laboratory of Pharmaceutical Analysis, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, GR-15771 Athens, Greece
| | - Anthi Parla
- Laboratory of Pharmaceutical Analysis, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, GR-15771 Athens, Greece
| | - Abuzar Kabir
- International Forensic Research Institute, Department of Chemistry and Biochemistry, Florida International University, Miami 33199 FL, USA
| | - Kenneth G Furton
- International Forensic Research Institute, Department of Chemistry and Biochemistry, Florida International University, Miami 33199 FL, USA
| | - Dimitra Gennimata
- Athens General Hospital "Korgialenio-Benakio National Red Cross" Erithrou Stavrou 1, 11526 Athens, Greece
| | - Victoria Samanidou
- Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece
| | - Irene Panderi
- Laboratory of Pharmaceutical Analysis, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, GR-15771 Athens, Greece.
| |
Collapse
|
4
|
AlThikrallah MKI, Idris AM, Elbashir AA, Elgorashe REE, Buzid A, Alnajjar AO. Development of Capillary Zone Electrophoresis Method for the Simultaneous Separation and Quantification of Metformin and Pioglitazone in Dosage Forms; and Comparison with HPLC Method. Molecules 2023; 28:1184. [PMID: 36770850 PMCID: PMC9919060 DOI: 10.3390/molecules28031184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 01/20/2023] [Accepted: 01/23/2023] [Indexed: 01/27/2023] Open
Abstract
A capillary zone electrophoretic (CZE) method was developed, validated, and applied for the assay of metformin (MET) and pioglitazone (PIO) in pharmaceutical formulations. The optimum running buffer composition was found to be 75 mmol/L phosphate buffer containing 30% acetonitrile (ACN) at pH 4.0. The optimum instrumental conditions were found to be injection time, 10 s; applied voltage, 25 kV; hydrodynamic injection pressure, 0.5 psi for 10 s, capillary temperature, 25 °C; and the detection wavelength, 210 nm. The quantifications were calculated based on the ratio of the peak areas of analytes to atenolol as an internal standard. The CZE method was validated in terms of accuracy (98.21-104.81%), intra- and inter-day precision of migration time and peak area (relative standard deviation ≤ 5%), linearity (correlation coefficients ≥ 0.9985), limit of detection (≤0.277 μg/mL), and limit of quantitation (≤0.315 μg/mL). The proposed method was applied for the analysis of PIO and MET both individually and in a combined dosage tablet formulation. All electrophoretic parameters were calculated and evaluated. A previously reported high-performance liquid chromatographic (HPLC) method was also applied to the same samples. A comprehensive comparison was then carried out for the analytical features of both methods CZE and HPLC. Comparable results were obtained with the advantage of reagent consumption and separation efficiency of CZE over HPLC and shorter analysis time by HPLC compared with CZE.
Collapse
Grants
- This research was supported by Deanship of Scientific Research, King Faisal University, Hofuf, Saudi Arabia (GRNT 2151) This research was supported by Deanship of Scientific Research, King Faisal University, Hofuf, Saudi Arabia (GRNT 2151)
- This research was supported by Deanship of Scientific Research, King Faisal University, Hofuf, Saudi Arabia (GRNT 2151) This research was supported by Deanship of Scientific Research, King Faisal University, Hofuf, Saudi Arabia (GRNT 2151)
Collapse
Affiliation(s)
| | - Abubakr M. Idris
- Department of Chemistry, College of Science, King Khalid University, Abha 62529, Saudi Arabia
- Research Center for Advanced Materials Science (RCAMS), King Khalid University, Abha 62529, Saudi Arabia
| | - Abdalla Ahmed Elbashir
- Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| | - Rafea E. E. Elgorashe
- Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| | - Alyah Buzid
- Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| | - Ahmed O. Alnajjar
- Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| |
Collapse
|
5
|
Pai S, Huang MQ, Maki K, Waldron M, Yoshikawa T, Keller T, Burnett J. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2021; 1176:122754. [PMID: 34052557 DOI: 10.1016/j.jchromb.2021.122754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 04/16/2021] [Accepted: 04/30/2021] [Indexed: 11/15/2022]
Abstract
Enarodustat, a potent, orally bioavailable, selective inhibitor of hypoxia inducible factor-Prolyl hydroxylase (HIF-PH), has been approved recently in Japan for the treatment of anemia in patients with chronic kidney disease (CKD). To evaluate the pharmacokinetics of enarodustat, a bioanalytical assay in human plasma was needed for the quantitation of enarodustat for both healthy subjects and patients with CKD. The UPLC-MS/MS method for the quantitation of enarodustat was initially validated in a bioanalytical laboratory in Japan to support clinical studies conducted in Japan, and then was transferred and validated in a bioanalytical laboratory in United States to support clinical studies conducted here. A cross-validation was successfully performed between the two bioanalytical laboratories using both quality control (QC) samples and incurred study samples. Enarodustat was fortified with its isotopically labeled internal standard in a 25 µL plasma aliquot and extracted with protein precipitation. The chromatographic separation was achieved on an Acquity UPLC BEH C18 (1.7 µm, 2.1 × 50 mm) column with gradient elution. The calibration curve range for the assay was 1.00-500 ng/mL. Assay precision, accuracy, linearity, selectivity, sensitivity and analyte stability covering sample storage and analysis were established. No interferences were observed from medications that may be co-administered along with enarodustat. The validated UPLC-MS-MS method at the US bioanalytical laboratory has been successfully applied to eight clinical studies for the determination of enarodustat concentrations in human plasma for both healthy subjects and patients with CKD.
Collapse
Affiliation(s)
- Sudhakar Pai
- Akros Pharma Inc., 302 Carnegie Center, Suite 300, Princeton, NJ 08540, USA.
| | - Mike Qingtao Huang
- Akros Pharma Inc., 302 Carnegie Center, Suite 300, Princeton, NJ 08540, USA
| | - Koichi Maki
- Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | | | | | - Tara Keller
- PPD Laboratories, 2244 Dabney Road, Richmond, VA 23230, USA
| | - James Burnett
- PPD Laboratories, 2244 Dabney Road, Richmond, VA 23230, USA
| |
Collapse
|
6
|
El‐Beshlawy MM, Abdel‐Haleem FM, Barhoum A. Molecularly Imprinted Potentiometric Sensor for Nanomolar Determination of Pioglitazone Hydrochloride in Pharmaceutical Formulations. ELECTROANAL 2021. [DOI: 10.1002/elan.202060141] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Menna M. El‐Beshlawy
- Department of Chemistry, Faculty of Women Ain Shams University Cairo 11757 Egypt
| | - Fatehy M. Abdel‐Haleem
- Chemistry Department, Faculty of Science Cairo University Giza 12613 Egypt
- Cairo University Center for Hazard Mitigation and Environmental Studies and Research, CHMESR Cairo University Giza 12613 Egypt
| | - Ahmed Barhoum
- Department of Chemistry, Faculty of Science Helwan University, Ain Helwan Cairo 11795 Egypt
- National Centre for Sensor Research, School of Chemical Sciences Dublin City University Dublin D 09 Ireland
| |
Collapse
|
7
|
Garmangani B, Ghaderi E, Amiri AA. Extraction of pioglitazone via dispersive liquid–liquid microextraction based on ionic liquids and its measurement in drug samples using high-performance liquid chromatography. JOURNAL OF THE IRANIAN CHEMICAL SOCIETY 2021. [DOI: 10.1007/s13738-020-02146-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Dey S, Basak S, De A, Alam SP, Hossain T, Saha A, Ghosh M, Karmakar T. Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. J Chromatogr Sci 2020; 58:309-322. [PMID: 31836899 DOI: 10.1093/chromsci/bmz116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 11/12/2019] [Accepted: 11/23/2019] [Indexed: 11/14/2022]
Abstract
Nateglinide (NAT) and Pioglitazone (PIO) are an antidiabetic drugs combination and currently under clinical trial in countries like Japan. In this study, an alternative, a simple, sensitive high-performance liquid chromatography method has been developed (limit of detection: 15 ng/mL and limit of quantification: 50 ng/mL) for simultaneous estimation of this drug combination in rat plasma. Most remarkably, bioavailability of NAT has been increased markedly on coadministration with PIO, than when it was administered alone. Thus, PIO is assumed to retard the catabolism of NAT by inhibiting metabolic liver-microsomal enzyme, especially CYP2C9. Using a Waters Nova-Pak C 18 column (150 × 3.9 mm, 4 μm) and a mobile phase of acetonitrile: 10 mM KH2PO4 (60: 40, V/V (volume by volume)) pH 3.5, the analysis was performed at 210 nm with a flow rate of 1.5 mL/min. In silico docking via molecular dynamics simulation revealed that NAT-CYP2C9 binding affinity may be reduced after PIO attachment, presumably due to the binding site overlapping of the two drugs. Thus, it has been proposed that NAT and PIO may be an efficient synergistic fixed dose combination against diabetes mellitus, and the above method can foster a simple but highly sensitive bioanalytical estimation for routine analysis.
Collapse
Affiliation(s)
- Suddhasattya Dey
- Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhan Nagar, Durgapur, West Bengal 713206, India
| | - Souvik Basak
- Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhan Nagar, Durgapur, West Bengal 713206, India
| | - Anjan De
- Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhan Nagar, Durgapur, West Bengal 713206, India
| | - Shahreja Parvez Alam
- Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhan Nagar, Durgapur, West Bengal 713206, India
| | - Tabassum Hossain
- Department of Chemical Technology, University of Calcutta, Kolkata, West Bengal 700009, India
| | - Achintya Saha
- Department of Chemical Technology, University of Calcutta, Kolkata, West Bengal 700009, India
| | - Manik Ghosh
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835215, India
| | - Tanushree Karmakar
- Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhan Nagar, Durgapur, West Bengal 713206, India
| |
Collapse
|
9
|
Kelani KM, Rezk MR, Badran OM, Elghobashy MR. Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1132:121803. [DOI: 10.1016/j.jchromb.2019.121803] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Revised: 09/10/2019] [Accepted: 09/11/2019] [Indexed: 11/28/2022]
|
10
|
Glitazone loaded fat enhances adiponectin production and inhibits breast cancer cell proliferation. Mol Biol Rep 2019; 46:6485-6494. [PMID: 31571108 DOI: 10.1007/s11033-019-05094-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Accepted: 09/22/2019] [Indexed: 10/25/2022]
Abstract
Obesity and diabetes are both associated risk factors for developing breast cancer and poor patient outcomes. Adipose cells are an important endocrine system and are the main producer of adiponectin, with lean patients having higher circulating levels. Patients with diabetes are often treated with thiazolidinediones, glitazones, which also increase adiponectin production. Importantly high circulating levels of adiponectin and treatment with glitazone are associated with increased breast cancer patient survival. This study investigates the potential of using adipose tissue laden with glitazones to act as a drug depot, increase adiponectin levels, and locally release glitazones to inhibit breast cancer cell proliferation. The breast cancer cell lines MCF-7 and MBA-MD-231, and the normal breast epithelial cell line MCF-10A were exposed to media containing a range of concentrations of recombinant adiponectin, pioglitazone, or conditioned media obtained from pioglitazone laden adipose tissue to determine the impact of the different treatments on cell proliferation. The MCF-7 cells demonstrated the greatest reduction in proliferation upon exposure to adiponectin and pioglitazone with lower reductions observed in the MDA-MD-231 and MCF-10a cell lines. All three cell lines exhibited reductions in proliferation in the presence of pioglitazone loaded adipose tissue. Additionally, adiponectin and pioglitazone levels were higher in the media from glitazone loaded adipose tissue. Drug loaded adipose tissue could potentially be used to deliver adiponectin and glitazone to breast cancer cells and inhibit proliferation. Future research will examine the potential efficacy of this treatment approach in vivo.
Collapse
|
11
|
Sher N, Fatima N, Perveen S, Siddiqui FA. Simultaneous determination of anti-diabetic drugs. BRAZ J PHARM SCI 2019. [DOI: 10.1590/s2175-97902019000217394] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
12
|
Zhang GQ, Li YS, Gao XF. An asynchronous-alternating merging-zone flow-injection gold nanoparticles probe method for determination of anti-diabetic pioglitazone hydrochloride medicine. NEW J CHEM 2018. [DOI: 10.1039/c7nj04492e] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A new method was established on the basis of coloration of gold nanoparticles by pioglitazone hydrochloride in acidic media.
Collapse
Affiliation(s)
- Guo-Qi Zhang
- School of Chemical Engineering, Sichuan University
- Chengdu 6100651
- China
| | - Yong-Sheng Li
- School of Chemical Engineering, Sichuan University
- Chengdu 6100651
- China
| | - Xiu-Feng Gao
- West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University
- Chengdu 610065
- China
| |
Collapse
|
13
|
Sanders WG, Li H, Zhuplatov I, He Y, Kim SE, Cheung AK, Agarwal J, Terry CM. Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection. J Control Release 2017; 264:237-246. [PMID: 28867378 DOI: 10.1016/j.jconrel.2017.08.036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 08/06/2017] [Accepted: 08/29/2017] [Indexed: 10/18/2022]
Abstract
The insulin sensitizing glitazone drugs, rosiglitazone (ROS) and pioglitazone (PGZ) both have anti-proliferative and anti-inflammatory effects and induce adipose tissue (fat) to produce the vaso-protective protein adiponectin. Stenosis due to intimal hyperplasia development often occurs after placement of arteriovenous synthetic grafts used for hemodialysis. This work was performed to characterize the in vitro and in vivo effects of ROS or PGZ incorporation in fat and to determine if fat/PGZ depots could decrease vascular hyperplasia development in a porcine model of hemodialysis arteriovenous graft stenosis. Powdered ROS or PGZ (6-6000μM) was mixed with fat explants and cultured. Drug release from fat was quantified by HPLC/MS/MS, and adiponectin and monocyte chemotactic protein-1 (MCP-1) levels in culture media were measured by ELISA. The effect of conditioned media from the culture of fat with ROS or PGZ on i) platelet-derived growth factor-BB (PDGF-BB)-stimulated proliferation of human venous smooth muscle cells (SMC) was measured by a DNA-binding assay, and ii) lipopolysaccharide (LPS)-induced human monocyte release of tumor necrosis factor-alpha (TNFα) was assessed by ELISA. In a porcine model, pharmacokinetics of PGZ from fat depots transplanted perivascular to jugular vein were assessed by HPLC/MS/MS, and retention of the fat depot was monitored by MRI. A porcine model of synthetic graft placed between carotid artery and ipsilateral jugular vein was used to assess effects of PGZ/fat depots on vascular hyperplasia development. Both ROS and PGZ significantly induced the release of adiponectin and inhibited release of MCP-1 from the fat. TNF production from monocytes stimulated with LPS was inhibited 50-70% in the presence of media conditioned by fat alone or fat and either drug. The proliferation of SMC was inhibited in the presence of media conditioned by fat/ROS cultures. Fat explants placed perivascular to the external jugular vein were retained, as confirmed by MRI at one week after placement. PGZ was detected in the fat depot, in the external jugular vein wall and in adjacent tissue at clinically relevant levels, whereas levels in plasma were below detection. External jugular vein exposed to fat incorporated with PGZ had increased adiponectin expression compared to vein exposed to fat alone. However, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatment with fat/PGZ depots compared to no treatment.
Collapse
Affiliation(s)
- William G Sanders
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA
| | - Huan Li
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA
| | - Ilya Zhuplatov
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA
| | - Yuxia He
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA
| | - Seong-Eun Kim
- Department of Radiology and Imaging Science, Utah Center for Advanced Imaging Research, University of Utah, 729 Arapeen Dr., Salt Lake City, UT, USA
| | - Alfred K Cheung
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA; Medical Service, Veterans Affairs Salt Lake City Healthcare System, 500 Foothill Dr., 151N, Salt Lake City, UT, USA
| | - Jayant Agarwal
- Division of Plastic and Reconstructive Surgery, School of Medicine, University of Utah, 30 N. 1900 E. 3B400, Salt Lake City, UT, USA
| | - Christi M Terry
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT, USA.
| |
Collapse
|
14
|
Chinnalalaiah R, Pigili R, Avanapu SR. Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. ANNALES PHARMACEUTIQUES FRANÇAISES 2016; 75:105-111. [PMID: 27659416 DOI: 10.1016/j.pharma.2016.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 07/08/2016] [Accepted: 07/22/2016] [Indexed: 11/16/2022]
Abstract
A liquid chromatography tandem mass spectrometry (LC-MS/MS) based method was developed for the simultaneous estimation of pioglitazone and its active metabolites in human plasma for applicability to pharmacokinetic studies. The chromatographic separation was carried on the reversed phase Peerless Basic C18, column (100×4.6mm, 5μm) at column temperature of 40°C using a binary mobile phase consisting of methanol: 5mM ammonium acetate in 0.1% formic acid (80:20, v/v). The mobile phase was run at a flow rate of 1mL/min and the sample injection was 10μL. The method utilized pioglitazone D4 (IS1) and 5-hydroxyl pioglitazone M-IV D4 (IS2) as an internal standard. The linearity of the method was validated over the range of 6.04-1503.21ng/mL for pioglitazone and 6.01-1496.28ng/mL for 5-hydroxyl pioglitazone. The mean extraction recovery of PIO & HPIO from the spiked plasma was found to be 94.92% for pioglitazone and 96.13% for 5-hydroxy pioglitazone. The developed method can be successfully employed in healthy human volunteers to monitor the pharmacokinetics profile of pioglitazone.
Collapse
Affiliation(s)
- R Chinnalalaiah
- Department of pharmaceutical chemistry, Joginpally B.R. Pharmacy College, Yenkapally(V), Amdapur X road, Moinabad R.R. district, 500075 Hyderabad, Telangana, India; Aizant drug research solutions, 500014 Hyderabad, Telangana, India.
| | - R Pigili
- Department of pharmaceutical chemistry, Joginpally B.R. Pharmacy College, Yenkapally(V), Amdapur X road, Moinabad R.R. district, 500075 Hyderabad, Telangana, India; Aizant drug research solutions, 500014 Hyderabad, Telangana, India
| | - S R Avanapu
- Department of pharmacology, Bhaskar pharmacy college, Moinabad, 500075 Hyderabad, Telangana, India
| |
Collapse
|
15
|
Al-Majed A, Bakheit AHH, Abdel Aziz HA, Alharbi H, Al-Jenoobi FI. Pioglitazone. PROFILES OF DRUG SUBSTANCES, EXCIPIENTS, AND RELATED METHODOLOGY 2016; 41:379-438. [PMID: 26940171 DOI: 10.1016/bs.podrm.2015.11.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Pioglitazone is a thiazolidinedione antidiabetic with actions similar to those of rosiglitazone. It is used in the management of type 2 diabetes mellitus and is prepared by reducing 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzilidene]-2,4-thiazolidinedione with sodium borohydride in the presence of a cobalt ion and dimethyl glyoxime. Ultraviolet spectroscopy shows maximum absorption at 270nm. Infrared spectroscopy shows principal peaks at wave numbers 3082, 2964, 1736, 1690, 1472, 1331, 1254, 1040, 841, 728cm(-1) (KBr disk). The determination method by high-performance liquid chromatography was linear over the range of 25-1500ng/mL of pioglitazone in plasma (r(2)>0.999). The within- and between-day precision values were in the range of 2.4-6.8%. The limit of quantitation of the method was 25ng/mL. It is well absorbed with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5h. It is metabolized by the hepatic cytochrome P450 enzyme system. Following oral administration, approximately 15-30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.
Collapse
Affiliation(s)
- A Al-Majed
- King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - A H H Bakheit
- King Saud University, Riyadh, Kingdom of Saudi Arabia
| | | | - H Alharbi
- King Saud University, Riyadh, Kingdom of Saudi Arabia
| | | |
Collapse
|
16
|
Prasad PS, Imam SS, Aqil M, Rizwan M, Sultana Y, Ali A. Validated reversed phase HPLC method for determination of pioglitazone hydrochloride in bulk drug and tablet formulations. JOURNAL OF ANALYTICAL CHEMISTRY 2015. [DOI: 10.1134/s106193481506012x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
17
|
Kawaguchi-Suzuki M, Bril F, Sanchez PP, Cusi K, Frye RF. A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 969:219-23. [DOI: 10.1016/j.jchromb.2014.08.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 08/11/2014] [Accepted: 08/13/2014] [Indexed: 10/24/2022]
|
18
|
Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 960:247-52. [DOI: 10.1016/j.jchromb.2014.04.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Revised: 04/15/2014] [Accepted: 04/19/2014] [Indexed: 01/09/2023]
|
19
|
Satheeshkumar N, Shantikumar S, Srinivas R. Pioglitazone: A review of analytical methods. J Pharm Anal 2014; 4:295-302. [PMID: 29403893 PMCID: PMC5761212 DOI: 10.1016/j.jpha.2014.02.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Revised: 01/30/2014] [Accepted: 02/28/2014] [Indexed: 11/30/2022] Open
Abstract
Pioglitazone is an oral anti-hyperglycemic agent. It is used for the treatment of diabetes mellitus type 2. It selectively stimulates nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma). It was the tenth-best-selling drug in the U.S. in 2008. This article examines published analytical methods reported so far in the literature for the determination of pioglitazone in biological samples and pharmaceutical formulations. They include various techniques like electrochemical methods, spectrophotometry, capillary electrophoresis, high-performance liquid chromatography, liquid chromatography–electrospray ionization-tandem mass spectrometry and high-performance thin layer chromatography.
Collapse
Affiliation(s)
- N Satheeshkumar
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Hyderabad (NIPER-H), Balanagar, Hyderabad 500037, India
| | - S Shantikumar
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Hyderabad (NIPER-H), Balanagar, Hyderabad 500037, India
| | - R Srinivas
- National Center for Mass Spectrometry, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500607, India
| |
Collapse
|
20
|
Sharma RN, Pancholi SS. HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats. Sci Pharm 2014; 82:555-70. [PMID: 25853068 PMCID: PMC4318181 DOI: 10.3797/scipharm.1401-18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Accepted: 03/13/2014] [Indexed: 11/22/2022] Open
Abstract
Carotid intima-media thickness is used as a surrogate marker for cardiovascular complications in diabetes mellitus. The combination of atorvastatin and pioglitazone was found to be effective in reducing the thickness of the carotid intima-media layer. The method of RP-HPLC coupled with a diode array detector (DAD) was developed for the pharmacokinetic interaction study of atorvastatin with pioglitazone and cholestyramine, respectively, in Wistar rats. Atorvastatin (ATR) and pioglitazone (PIO) were resolved on a C18 column with a mobile phase composed of 48% methanol, 19% acetonitrile, and 33% 10 mM ammonium formate (v/v/v; pH 3.5±0.3, by formic acid) and a 260 nm detection wavelength on the diode array detector. The method was validated according to international standards with good reproducibility and linear response; mean (r) 0.9987 and 0.9972 to ATR and PIO, respectively. The coefficients of variation of intra- and interassay precision ranged between 4.95–8.12 and 7.29–9.67, respectively. Pharmacokinetic parameters were determined in rats following an oral administration of atorvastatin in the presence and absence of pioglitazone and also with cholestyramine. Compared with the control given atorvastatin alone, the Cmax and AUC of atorvastatin were merely unchanged in rats with the co-administration of pioglitazone, while they decreased by nearly 21 and 15%, respectively, with the concurrent use of cholestyramine. There were no significant changes in Tmax and the plasma half-life (T1/2) of atorvastatin in both cases. The performed experiment demonstrated that the presented method was suitable for the estimation and pharmacokinetic interaction study of atorvastatin with pioglitazone and cholestyramine in Wistar rat plasma.
Collapse
Affiliation(s)
- Ritesh N Sharma
- Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana-Gojaria Highway, Gujarat, 382014, India
| | | |
Collapse
|
21
|
Du B, Pang L, Yang Y, Shen G, Zhang Z. Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 951-952:143-8. [DOI: 10.1016/j.jchromb.2014.01.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Revised: 01/06/2014] [Accepted: 01/10/2014] [Indexed: 10/25/2022]
|
22
|
Jafari MT, Kamfirozi M, Jazan E, Ghoreishi SM. Selective extraction and analysis of pioglitazone in cow plasma using a molecularly imprinted polymer combined with ESI ion mobility spectrometry. J Sep Sci 2014; 37:573-9. [DOI: 10.1002/jssc.201301206] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Revised: 12/07/2013] [Accepted: 12/08/2013] [Indexed: 11/12/2022]
Affiliation(s)
| | | | - Elham Jazan
- Department of Chemistry; Islamic Azad University; Shahreza Branch; Shahreza Isfahan Iran
| | | |
Collapse
|
23
|
Peng C, Zhang T, Zhao G, Wang S. Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS. J Pharm Anal 2013; 3:402-407. [PMID: 29403846 PMCID: PMC5761013 DOI: 10.1016/j.jpha.2013.04.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Accepted: 04/28/2013] [Indexed: 11/25/2022] Open
Abstract
A simple and rapid gas chromatography/mass spectrometry (GC/MS) analysis method was developed for the determination of fat-soluble parts of sinapis semina. Four major compounds were chosen as marker compounds to evaluate the method. Various extraction techniques were evaluated and the greatest efficiency was observed with sonication extraction using diethyl ether. The method was valuated as follows: acceptable apparatus suitability was obtained by testing the resolutions, tailing factors and theoretical plate number of the marker compounds; the precision and reproducibility, expressed as relative standard deviation (RSD), fell within the prescribed limits. Eight samples of sinapis semina collected from markets in Xi'an were monitored by using the method. The fingerprints of those samples were analyzed by hierarchical cluster analysis (HCA) similarity analysis. The result indicated that the combination of fingerprint and HCA could be used to analyze sinapis semina from different habitats.
Collapse
Affiliation(s)
- Cheng Peng
- School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China
| | - Tao Zhang
- School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China
| | - Gang Zhao
- School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China
| | - Sicen Wang
- School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China
| |
Collapse
|
24
|
Pedada KK, Zhou X, Jogiraju H, Carroll RT, Geldenhuys WJ, Lin L, Anderson DJ. A quantitative LC-MS/MS method for determination of thiazolidinedione mitoNEET ligand NL-1 in mouse serum suitable for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 945-946:141-6. [PMID: 24334225 DOI: 10.1016/j.jchromb.2013.11.048] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 11/14/2013] [Accepted: 11/22/2013] [Indexed: 10/26/2022]
Abstract
Thiazolidinedione (TZD) compounds have shown promise as antidiabetic, antibiotics, antifungal and neuroprotective agents. The mitochondrial effect of a novel mitoNEET ligand, NL-1 {5-[(3,5-di-tert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione}, and other TZD compounds, is a newly proposed mechanism for the neuroprotective action of these TZD compounds. In this work, a sensitive LC-MS/MS assay has been developed and validated for quantification of NL-1 in mouse serum. Sample preparation involved an acetonitrile protein precipitation procedure with addition of an internal standard NL-2 {5-[(4-hydroxy-3,5-dimethyl-phenyl)methyl]thiazolidine-2,4-dione}. LC-MS/MS analysis utilized a Columbus C-18 HPLC column (2mm×50mm, 5μm). Chromatography employed a multiple step gradient program that featured a steep linear gradient (25-95% in 0.5min) of 15μM ammonium acetate (additive for eliminating carry-over) in 2% methanol mixing with increasing proportions of 100% methanol. The HPLC was interfaced to a QTrap 5500 mass spectrometer (AB Sciex) equipped with an electrospray ionization source used in a negative ionization mode. Multiple reaction monitoring (MRM) of m/z 334→263 for NL-1 and m/z 250→179 for NL-2 was done. The method had a linear range of at least 1-100ng/mL in serum. The intra-assay and inter-assay percent coefficient of variation (%CV) were less than 4% and accuracies (%RE) ranged from -2.7% to 2.0%. The analytical procedure gave 96-115% absolute extraction recovery of NL-1. The relative matrix effect was measured and found to be insignificant. The analyte in serum was confirmed to be stable during storage and treatment. The method is suitable for pharmacokinetic (PK) studies of the parent drug NL-1 based on the preliminary serum results from dosed NL-1 mouse studies.
Collapse
Affiliation(s)
- Kiran K Pedada
- Department of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, United States
| | - Xiang Zhou
- Department of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, United States
| | - Harini Jogiraju
- Department of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, United States
| | - Richard T Carroll
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, United States
| | - Werner J Geldenhuys
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, United States
| | - Li Lin
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, United States
| | - David J Anderson
- Department of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, United States.
| |
Collapse
|
25
|
Peraman R, Mallikarjuna S, Ammineni P, Kondreddy VK. RP-HPLC method development and validation for simultaneous estimation of atorvastatin calcium and pioglitazone hydrochloride in pharmaceutical dosage form. J Chromatogr Sci 2013; 52:1038-42. [PMID: 24152592 DOI: 10.1093/chromsci/bmt156] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
A simple, selective, rapid, precise and economical reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed for simultaneous estimation of atorvastatin calcium (ATV) and pioglitazone hydrochloride (PIO) from pharmaceutical formulation. The method is carried out on a C8 (25 cm × 4.6 mm i.d., 5 μm) column with a mobile phase consisting of acetonitrile (ACN):water (pH adjusted to 6.2 using o-phosphoric acid) in the ratio of 45:55 (v/v). The retention time of ATV and PIO is 4.1 and 8.1 min, respectively, with the flow rate of 1 mL/min with diode array detector detection at 232 nm. The linear regression analysis data from the linearity plot showed good linear relationship with a correlation coefficient (R(2)) value for ATV and PIO of 0.9998 and 0.9997 in the concentration range of 10-80 µg mL(-1), respectively. The relative standard deviation for intraday precision has been found to be <2.0%. The method is validated according to the ICH guidelines. The developed method is validated in terms of specificity, selectivity, accuracy, precision, linearity, limit of detection, limit of quantitation and solution stability. The proposed method can be used for simultaneous estimation of these drugs in marketed dosage forms.
Collapse
Affiliation(s)
- Ramalingam Peraman
- Division of Pharmaceutical Analysis and Quality Assurance, Center for Pharmaceutical Research (CPR), Raghavendra Institute of Pharmaceutical Education and Research (RIPER), K.R. Palli Cross, Chiyyedu (Post), Anantapur, AP 515721, India
| | - Sasikala Mallikarjuna
- Division of Pharmaceutical Analysis and Quality Assurance, Center for Pharmaceutical Research (CPR), Raghavendra Institute of Pharmaceutical Education and Research (RIPER), K.R. Palli Cross, Chiyyedu (Post), Anantapur, AP 515721, India
| | - Pravalika Ammineni
- Division of Pharmaceutical Analysis and Quality Assurance, Center for Pharmaceutical Research (CPR), Raghavendra Institute of Pharmaceutical Education and Research (RIPER), K.R. Palli Cross, Chiyyedu (Post), Anantapur, AP 515721, India
| | - Vinod kumar Kondreddy
- Division of Pharmaceutical Analysis and Quality Assurance, Center for Pharmaceutical Research (CPR), Raghavendra Institute of Pharmaceutical Education and Research (RIPER), K.R. Palli Cross, Chiyyedu (Post), Anantapur, AP 515721, India
| |
Collapse
|
26
|
THE APPLICATION OF THIOLATED CHITOSAN IN CONSTRUCTION OF ELECTROCHIMICAL BIOSENSOR. ACTA POLYM SIN 2013. [DOI: 10.3724/sp.j.1105.2013.12244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Modi DK, Patel BH. RAPID AND SENSITIVE SIMULTANEOUS ESTIMATION OF METFORMIN HYDROCHLORIDE AND PIOGLITAZONE HYDROCHLORIDE IN TABLET FORMULATION BY HPTLC METHOD. J LIQ CHROMATOGR R T 2013. [DOI: 10.1080/10826076.2012.673202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Darshana K. Modi
- a K. B. Institute of Pharmaceutical Education and Research, Department of Pharmaceutical Chemistry , Kadi Sarva Vishwavidyalaya , Gandhinagar , Gujarat , India
| | - Bhavesh H. Patel
- a K. B. Institute of Pharmaceutical Education and Research, Department of Pharmaceutical Chemistry , Kadi Sarva Vishwavidyalaya , Gandhinagar , Gujarat , India
| |
Collapse
|
28
|
Calixto LA, Bonato PS. Combination of hollow-fiber liquid-phase microextraction and capillary electrophoresis for pioglitazone and its main metabolites determination in rat liver microsomal fraction. Electrophoresis 2013; 34:862-9. [DOI: 10.1002/elps.201200430] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 10/25/2012] [Accepted: 11/08/2012] [Indexed: 01/25/2023]
Affiliation(s)
- Leandro Augusto Calixto
- Department of Physics and Chemistry, Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; Ribeirão Preto; Brazil
| | - Pierina Sueli Bonato
- Department of Physics and Chemistry, Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; Ribeirão Preto; Brazil
| |
Collapse
|
29
|
Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A, Landreth GE. The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol 2013; 71:929-36. [PMID: 23358645 DOI: 10.1007/s00280-013-2084-2] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2013] [Accepted: 01/08/2013] [Indexed: 01/03/2023]
Abstract
PURPOSE The peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear hormone receptor family, represents a target in glioma therapy due to its antineoplastic effects in vitro on human glioma cell lines. We investigate the antineoplastic effects of the PPARγ agonist pioglitazone (pio) in a human glioma xenograft model to define the minimal required dose to induce antineoplastic effects. Additionally, we assess the ability of pio to cross the blood-brain barrier by measuring brain parenchymal concentration after oral administration. METHODS Human LN-229 cells were injected into the striatum of Balb/cJHanHsd-Prkdc-scid mice. Tumor volumes, invasion, proliferation and parenchymal pio concentrations were measured in this xenograft model after continuous intracerebral drug administration through an osmotic pump or after oral administration. RESULTS Continuous intracerebral or oral administration of pio reduced tumor volumes, invasion, and proliferation in vivo. To achieve a significant antineoplastic effect, pio needed to be dosed at 240 PPM in the oral group and >1 μM when delivered intracerebrally. After oral pio administration, the drug reached >1 nM levels in brain parenchyma. CONCLUSIONS These data indicate that pioglitazone crosses the blood-brain barrier and has antineoplastic effects in this glioma xenograft model and may be of potential use in treatment of malignant gliomas.
Collapse
Affiliation(s)
- Christian Grommes
- Department of Neuroscience, Case Western Reserve University, Cleveland, OH, USA.
| | | | | | | | | | | |
Collapse
|
30
|
Zhang X, Peng Y, Wan P, Yin L, Wang G, Sun J. Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. J Chromatogr Sci 2013; 52:52-8. [PMID: 23293039 DOI: 10.1093/chromsci/bms204] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A high-performance liquid chromatography-tandem mass spectrometry method was developed for the simultaneous determination of metformin (MET) and pioglitazone (PIO) in dogs. To increase the reliability of the method, moroxydine (IS-1) and rosiglitazone (IS-2) were used as internal standards for MET and PIO, respectively. The analytes were extracted from beagle dog plasma by a one-step protein precipitation. Chromatographic separation was performed on a Phenomenex Synergi POLAR-RP 80A column (250 × 4.6 mm, 4 µm). The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2. The lower limit of quantitation values were 2 and 1 ng/mL for MET and PIO, respectively. The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.
Collapse
Affiliation(s)
- Xueyuan Zhang
- 1Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, PR China
| | | | | | | | | | | |
Collapse
|
31
|
Xavier CM, Basavaiah K. Implementation of Quality by Design for the Development and Validation of Pioglitazone Hydrochloride by RP-UPLC with Application to Formulated Forms. ACTA ACUST UNITED AC 2012. [DOI: 10.5402/2012/592849] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Quality by Design (QbD) is a philosophy that refines the level of knowledge associated with a product that uses process understanding to deliver a product with the desired critical quality attributes. The objective of this study was to develop an integrated multivariate QbD approach to develop and quantify the constituent concentrations of pioglitazone hydrochloride (PGZ) drug in its pure and formulated forms. To facilitate studies investigating the determination of PGZ in bulk drug and its pharmaceutical formulations, a rapid UPLC method was developed and validated for the determination of PGZ accompanied by its degradation studies in different stress conditions. The method fulfilled validation criteria and was shown to be sensitive, with limits of detection (LOD) and quantitation (LOQ) of 0.01 and 0.05 μg mL−1, respectively. The percent relative standard deviations for robustness and ruggedness were observed within the range of 0.1–1.74. The calibration graph was linear in the range of 0.05–300 μg mL−1. The applicability of the method was shown by analysis of formulated drug samples and spiked human urine. The proposed method can be used for routine analysis in quality controlled laboratories for its bulk and formulated product and this is the first reported UPLC method for the assay of PGZ.
Collapse
Affiliation(s)
- Cijo M. Xavier
- Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore, Karnataka 570006, India
| | - Kanakapura Basavaiah
- Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore, Karnataka 570006, India
| |
Collapse
|
32
|
Sarraf M, Lu L, Ye S, Reiter MJ, Greyson CR, Schwartz GG. Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. Cardiovasc Drugs Ther 2012; 26:195-204. [PMID: 22450779 DOI: 10.1007/s10557-012-6384-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
PURPOSE Despite favorable metabolic and vascular effects, thiazolidinedione (TZD) drugs have not convincingly reduced cardiovascular mortality in clinical trials, raising the possibility of countervailing, off-target effects. We previously showed that TZDs block cardiac ATP-sensitive potassium (K(ATP)) channels in pigs. In this study, we investigated whether TZDs affect onset, spectral characteristics, and mortality of ischemic ventricular fibrillation (VF) and whether such effects are recapitulated by a non-selective K(ATP) blocker (glyburide) or a mitochondrial K(ATP) blocker (5-hydroxydecanoate). METHODS A total of 121 anesthetized pigs were pre-treated with TZD (pioglitazone or rosiglitazone, 1 mg/kg IV, resulting in clinically relevant plasma concentrations), glyburide (1 mg/kg IV), 5-hydroxydecanoate (5 mg/kg IV) or inert vehicle. Ischemia was produced by occlusion of the left anterior descending coronary artery. In a subset of pigs treated with rosiglitazone or vehicle, ischemic preconditioning was performed. RESULTS VF developed in all but 6 pigs. In non-preconditioned pigs, onset of VF occurred sooner with pioglitazone (11±3 min, p<0.05) or rosiglitazone (14±3 min, p=0.06) than with vehicle (20±2 min). Defibrillation of VF was successful in 44% of pigs treated with vehicle, compared with 0% with pioglitazone (p=0.057) and 33% with rosiglitazone (NS). After ischemic preconditioning, defibrillation was successful in 62% of pigs treated with vehicle, compared with 26% treated with rosiglitazone (p=0.03). TZDs attenuated slowing of conduction due to ischemia and shifted ECG power spectra during VF toward higher frequencies. All effects of TZDs were recapitulated by glyburide, but not by 5-hydroxydecanoate, supporting an interaction of TZDs with the sarcolemmal K(ATP) channel. CONCLUSION In a porcine model, TZDs promote onset and increase mortality of ischemic VF, associated with alterations of conduction and VF spectral characteristics. Similar effects in a clinical setting might adversely impact cardiovascular mortality.
Collapse
Affiliation(s)
- Mohammad Sarraf
- Cardiology Section, VA Medical Center and University of Colorado, Denver, CO, USA
| | | | | | | | | | | |
Collapse
|
33
|
Kumari Karra V, Rao Pilli N, Kumar Inamadugu J, Seshagiri Rao J. Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. J Pharm Anal 2012; 2:167-173. [PMID: 29403738 PMCID: PMC5760890 DOI: 10.1016/j.jpha.2012.01.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Accepted: 01/09/2012] [Indexed: 11/19/2022] Open
Abstract
A simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay method has been developed and fully validated for simultaneous quantification of pioglitazone and candesartan in human plasma. Irbesartan was used as an internal standard. The analytes were extracted from human plasma samples by solid-phase extraction technique using a Strata-X 33 μm polymeric sorbent. The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min. The calibration curves obtained were linear (r≥0.99) over the concentration range of 15–3000 ng/mL for pioglitazone and 5–608 ng/mL for candesartan. The results of the intra- and inter-day precision and accuracy studies were well within the acceptable limits. A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day. The proposed method was found to be applicable to clinical studies.
Collapse
Affiliation(s)
- Vijaya Kumari Karra
- University College of Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad-500085, India
| | - Nageswara Rao Pilli
- University College of Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad-500085, India
| | - Jaswanth Kumar Inamadugu
- Analytical and Environmental Chemistry Division, Department of Chemistry, Sri Venkateswara University, Tirupati-517502, India
| | - J.V.L.N. Seshagiri Rao
- College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530003, India
- Corresponding author. +91 9491766577.
| |
Collapse
|
34
|
Kale D, Kakde R. Simultaneous determination of pioglitazone, metformin, and glimepiride in pharmaceutical preparations using HPTLC method. JPC-J PLANAR CHROMAT 2011. [DOI: 10.1556/jpc.24.2011.4.11] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
35
|
Lakshmi KS, Rajesh T. Separation and Quantification of Eight Antidiabetic Drugs on A High-Performance Liquid Chromatography: Its Application to Human Plasma Assay. ISRN PHARMACEUTICS 2011; 2011:521353. [PMID: 22389851 PMCID: PMC3263720 DOI: 10.5402/2011/521353] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Accepted: 05/05/2011] [Indexed: 11/23/2022]
Abstract
An analytical method based on isocratic reverse phase high-performance liquid chromatography was developed and validated for the separation and quantification of eight antidiabetic drugs: rosiglitazone, pioglitazone, glipizide, gliclazide, repaglinide, nateglinide, glibenclamide, and glimepiride for their application in human plasma assay. Metformin is used as internal standard. Analysis was done on Onyx monolithic C18 column (100×4.6 mm, i.d., 5 μm) using a mixture of 0.05% formic acid in water and methanol in the ratio of 42 : 58 (v/v) fixed at a flow rate of 0.5 mL/min, and they were monitored at 234 nm. Separation was achieved in less than 20 min. The calibration curves were linear in the range of 50–2000 ng/mL. The method was validated for its recovery, intra- and interday precision, stability, specificity, and selectivity. Plasma samples were prepared using solid-phase extraction of analytes. Hence, the developed method was found to be suitable for the routine analysis of selected antidiabetic drugs in biological matrices.
Collapse
Affiliation(s)
- Karunanidhi S. Lakshmi
- Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur, Tamil Nadu 603203, India
| | - Tirumala Rajesh
- Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur, Tamil Nadu 603203, India
| |
Collapse
|
36
|
Ye X, Tang M, Liu J, Wang X, Ma L, Zheng H, Hu J, Chen X, Duan X, Chen L. Development and validation of a UPLC-MS/MS method for quantification of SKLB010, an investigational anti-inflammatory compound, and its application to pharmacokinetic studies in beagle dogs. J Pharm Biomed Anal 2011; 56:366-72. [PMID: 21680128 DOI: 10.1016/j.jpba.2011.05.031] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 05/15/2011] [Accepted: 05/20/2011] [Indexed: 02/05/2023]
Abstract
SKLB010 is currently under development as a potential therapeutic agent for the treatment of acute hepatitis and rheumatoid arthritis. The purpose of this paper was to investigate the pre-clinical pharmacokinetics of SKLB010 in beagle dogs. An ultra performance liquid chromatographic tandem mass spectroscopy (UPLC-MS/MS) method was developed and validated for the quantitative determination of SKLB010 in dog plasma, using rosiglitazone as the internal standard (I.S.). Plasma samples were prepared by a simple solid phase extraction (SPE) method. The analyte and internal standard were separated by an Acquity UPLC BEH C18 (2.1 mm × 50 mm) column with a mobile phase of methanol-water (80/20, v/v) over 2 min. Detection was based on the multiple reaction monitoring with the precursor-to-product ion transitions m/z 234.10→147.92 (SKLB010) and m/z 356.15→150.00 (I.S.). The method was validated according to FDA guidelines on bio-analytical method validation. The selectivity, sensitivity, linearity, accuracy, precision, extraction recovery, ion suppression and stability were within the acceptable ranges. The method described above was successfully applied to reveal the single- and multi-pharmacokinetic profiles of SKLB010 in beagle dogs and should be extendable to pharmacokinetic studies in other species as well.
Collapse
Affiliation(s)
- Xia Ye
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Farouk M, Abdel-Satar O, Abdel-Aziz O, Shaaban M. Validated spectrophotometric methods for determination of some oral hypoglycemic drugs. Drug Discov Ther 2011; 5:41-52. [DOI: 10.5582/ddt.v5.1.41] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | | | | | - Maya Shaaban
- Faculty of Pharmacy, Egyptian Russian University
| |
Collapse
|
38
|
High-performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum. CHINESE J CHEM 2010. [DOI: 10.1002/cjoc.201090333] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
39
|
Application of the DBS methodology to a toxicokinetic study in rats and transferability of analysis between bioanalytical laboratories. Bioanalysis 2010; 2:1489-99. [DOI: 10.4155/bio.10.88] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: There are little published data on either the comparison of liquid blood and dried blood spots (DBS) analyses or the ability to generate comparable DBS data at different analytical laboratories. We assess the comparative results of samples stored as liquid blood and DBS. We also determine the transferability of DBS samples by comparing the analysis at two laboratories. Results: Bioanalytical methods for the analysis of pioglitazone in DBS and liquid blood samples were validated to US FDA guidelines. Pharmacokinetic data generated from DBS and liquid blood samples demonstrated area under the time-concentration profile (0–24 h) values within 3% of each other and maximum plasma concentration values within 7% of each other. Comparing DBS sample results at different laboratories showed more than 99% of results agreeing within 20%. Conclusions: The results indicate that comparable concentration results are obtained from DBS and whole blood samples within the same laboratory, indicating that changing between the two matrices is viable. The comparable results of DBS samples analyzed at two laboratories using different analytical methodologies demonstrate that the technique is robust and transferable.
Collapse
|
40
|
Ulu ST, Elmalı FT. UV–Second Derivative Spectrophotometric and Colorimetric Methods for the Determination, Validation and Thermogravimetric Analysis of New Oral Antidiabetic Pioglitazone in Pure and Pharmaceutical Preparations. ANAL LETT 2009. [DOI: 10.1080/00032710903137483] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
Tahmasebi E, Yamini Y, Saleh A. Extraction of trace amounts of pioglitazone as an anti-diabetic drug with hollow fiber liquid phase microextraction and determination by high-performance liquid chromatography-ultraviolet detection in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1923-9. [DOI: 10.1016/j.jchromb.2009.05.033] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2009] [Revised: 05/12/2009] [Accepted: 05/16/2009] [Indexed: 10/20/2022]
|
42
|
Gumieniczek A, Hopkała H, Berecka A. Reversed‐Phase Thin‐Layer Chromatography of Three New Oral Antidiabetics and Densitometric Determination of Pioglitazone. J LIQ CHROMATOGR R T 2009. [DOI: 10.1081/jlc-120039418] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Anna Gumieniczek
- a Department of Medicinal Chemistry , Medical University of Lublin , Chodźki 6, 20‐093 , Lublin , Poland
| | - Hanna Hopkała
- a Department of Medicinal Chemistry , Medical University of Lublin , Chodźki 6, 20‐093 , Lublin , Poland
| | - Anna Berecka
- a Department of Medicinal Chemistry , Medical University of Lublin , Chodźki 6, 20‐093 , Lublin , Poland
| |
Collapse
|
43
|
Shirkhedkar A, Surana S. Application of a stability-indicating densitometric RP-TLC method for analysis of pioglitazone hydrochloride in the bulk material and in pharmaceutical formulations. JPC-J PLANAR CHROMAT 2009. [DOI: 10.1556/jpc.22.2009.3.6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
44
|
AL-ARFAJ NA, AL-ABDULKAREEM EA, ALY FA. Flow-Injection Chemiluminometric Determination of Pioglitazone HCl by Its Sensitizing Effect on the Cerium-Sulfite Reaction. ANAL SCI 2009; 25:401-6. [DOI: 10.2116/analsci.25.401] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Nawal A. AL-ARFAJ
- Department of Chemistry, College of Science, Women Student—Medical Studies and Science Sections, King Saud University
| | - Eman A. AL-ABDULKAREEM
- Department of Chemistry, College of Science, Women Student—Medical Studies and Science Sections, King Saud University
| | - Fatma A. ALY
- Department of Chemistry, College of Science, Women Student—Medical Studies and Science Sections, King Saud University
| |
Collapse
|
45
|
Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 2008; 52:869-81. [PMID: 18755353 PMCID: PMC2633943 DOI: 10.1016/j.jacc.2008.04.055] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2008] [Revised: 04/22/2008] [Accepted: 04/29/2008] [Indexed: 01/14/2023]
Abstract
OBJECTIVES Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone modulates inflammation through PPARalpha mechanisms. BACKGROUND The thiazolidinediones (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPARgamma agonists used to treat type 2 diabetes (T2DM). Despite evidence for TZDs limiting inflammation and atherosclerosis, questions exist regarding differential responses to TZDs. In a double-blinded, placebo-controlled 16-week trial among recently diagnosed T2DM subjects (n = 34), pioglitazone-treated subjects manifested lower triglycerides and lacked the increase in soluble vascular cell adhesion molecules (sVCAM)-1 evident in the placebo group. Previously we reported PPARalpha but not PPARgamma agonists could repress VCAM-1 expression. Since both triglyceride-lowering and VCAM-1 repression characterize PPARalpha activation, we studied pioglitazone's effects via PPARalpha. METHODS Pioglitazone effects on known PPARalpha responses--ligand binding domain activation and PPARalpha target gene expression--were tested in vitro and in vivo, including in wild-type and PPARalpha-deficient cells and mice, and compared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists. RESULTS Pioglitazone repressed endothelial TNFalpha-induced VCAM-1 messenger ribonucleic acid expression and promoter activity, and induced hepatic IkappaBalpha in a manner dependent on both pioglitazone exposure and PPARalpha expression. Pioglitazone also activated the PPARalpha ligand binding domain and induced PPARalpha target gene expression, with in vitro effects that were most pronounced in endothelial cells. In vivo, pioglitazone administration modulated sVCAM-1 levels and IkappaBalpha expression in wild-type but not PPARalpha-deficient mice. CONCLUSIONS Pioglitazone regulates inflammatory target genes in hepatic (IkappaBalpha) and endothelial (VCAM-1) settings in a PPARalpha-dependent manner. These data offer novel mechanisms that may underlie distinct TZD responses.
Collapse
Affiliation(s)
- Gabriela Orasanu
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Ouliana Ziouzenkova
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Pallavi R. Devchand
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Vedika Nehra
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Osama Hamdy
- Clinical Research Center, Joslin Diabetes Center, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Edward S. Horton
- Clinical Research Center, Joslin Diabetes Center, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Jorge Plutzky
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
46
|
Characteristics of new composite- and classical potentiometric sensors for the determination of pioglitazone in some pharmaceutical formulations. J Pharm Biomed Anal 2008; 48:57-61. [DOI: 10.1016/j.jpba.2008.04.029] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2008] [Revised: 04/28/2008] [Accepted: 04/30/2008] [Indexed: 11/19/2022]
|
47
|
Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. Drug Metab Dispos 2007; 36:73-80. [PMID: 17913794 DOI: 10.1124/dmd.107.018010] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
We studied the effects of the CYP2C8 inhibitor trimethoprim and CYP2C8 genotype on the pharmacokinetics of the antidiabetic pioglitazone. In a randomized crossover study, 16 healthy volunteers with the CYP2C8(*)1/(*)1 (n = 8), (*)1/(*)3 (n = 5), or (*)3/(*)3 (n = 3) genotype ingested 160 mg of trimethoprim or placebo twice daily for 6 days. On day 3, they ingested 15 mg of pioglitazone. The effects of trimethoprim on pioglitazone were characterized in vitro. Trimethoprim raised the area under the plasma pioglitazone concentration-time curve (AUC(0-infinity)) by 42% (p < 0.001) and decreased the formation rates of pioglitazone metabolites M-IV and M-III (p < 0.001). During the placebo phase, the weight-adjusted AUC(0-infinity) of pioglitazone was 34% smaller in the CYP2C8(*)3/(*)3 group and 26% smaller in the CYP2C8(*)1/(*)3 group than in the CYP2C8(*)1/(*)1 group (p < 0.05). Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 muM), predicting the in vivo interaction. In conclusion, drug interactions and pharmacogenetics affecting the CYP2C8 enzyme may change the safety of pioglitazone.
Collapse
Affiliation(s)
- Aleksi Tornio
- Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
| | | | | | | |
Collapse
|
48
|
Gumieniczek A, Berecka A, Matosiuk D, Hopkała H. Standardized reversed-phase thin-layer chromatographic study of the lipophilicity of five anti-diabetic thiazolidinediones. JPC-J PLANAR CHROMAT 2007. [DOI: 10.1556/jpc.20.2007.4.5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
49
|
Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99:44-51. [PMID: 16867170 DOI: 10.1111/j.1742-7843.2006.pto_437.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Our objective was to identify the cytochrome P450 (CYP) enzymes that metabolise pioglitazone and to examine the effects of the CYP2C8 inhibitors montelukast, zafirlukast, trimethoprim and gemfibrozil on pioglitazone metabolism in vitro. The effect of different CYP isoform inhibitors on the elimination of a clinically relevant concentration of pioglitazone (1 microM) and the formation of the main primary metabolite M-IV were studied using pooled human liver microsomes. The metabolism of pioglitazone by CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 was investigated using human recombinant CYP isoforms. In particular, the inhibitors of CYP2C8, but also those of CYP3A4, markedly inhibited the elimination of pioglitazone and the formation of M-IV by HLM. Inhibitors selective to other CYP isoforms had a minor effect only. Of the recombinant isoforms, CYP2C8 (20 pmol/ml) metabolised pioglitazone markedly (56% in 60 min.), and also CYP3A4 had a significant effect (37% in 60 min.). Montelukast, zafirlukast, trimethoprim and gemfibrozil inhibited pioglitazone elimination in HLM with IC50 values of 0.51 microM, 1.0 microM, 99 microM and 98 microM, respectively, and the formation of the metabolite M-IV with IC50 values of 0.18 microM, 0.78 microM, 71 microM and 59 microM, respectively. In conclusion, pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro. CYP2C9 is not significantly involved in the elimination of pioglitazone. The effect of different CYP2C8 inhibitors on pioglitazone pharmacokinetics needs to be evaluated also in vivo because, irrespective of their in vitro CYP2C8 inhibitory potency, their pharmacokinetic properties may affect the extent of interaction.
Collapse
Affiliation(s)
- Tiina Jaakkola
- Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | | | | | | |
Collapse
|
50
|
Bhushan R, Gupta D, Jain A. TLC supplemented by UV spectrophotometry compared with HPLC for separation and determination of some antidiabetic drugs in pharmaceutical preparations. JPC-J PLANAR CHROMAT 2006. [DOI: 10.1556/jpc.19.2006.4.6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|